Login
Search
Search
0 Dates
2026
2025
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
CPC 2025
CPC 2026
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
Beyond clinical risk scores in pulmonary arterial hypertension: does invasive hemodynamic assessment provide additional value?
Session:
Sessão de Posters 57 - Hipertensão arterial pulmonar: estratificação de risco, hemodinâmica e prognóstico
Speaker:
Adriana Henriques Silva
Congress:
CPC 2026
Topic:
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
Theme:
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
Subtheme:
21.3 Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure – Diagnostic Methods
Session Type:
Posters Eletrónicos
FP Number:
---
Authors:
Adriana Silva; Sofia Alegria; Paula Fazendas; Filipa Ferreira; Bárbara Ferreira; Ana Cláudia Vieira; Débora Repolho; João Luz; Ana Rita Pereira; Otília Simões; Hélder Pereira
Abstract
<p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Calibri"><strong>Background:</strong> Accurate risk stratification in pulmonary arterial hypertension (PAH) is essential for prognosis and treatment selection. Current multiparametric scores, such as REVEAL Lite and COMPERA, rely predominantly on clinical and biochemical variables, without incorporating invasive hemodynamic markers that are known strong predictors of outcome.</span></span></p> <p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Calibri"><strong>Purpose:</strong> To determine whether invasive hemodynamic variables provide incremental prognostic value beyond established clinical risk scores in PAH.</span></span></p> <p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Calibri"><strong>Methods:</strong> We prospectively followed 78 PAH patients (pts) for 12 months in a referral center. The composite endpoint included death, lung transplantation, initiation of intravenous prostanoids, or unscheduled hospitalization. Baseline right-heart catheterization was performed according to current guidelines. Prognostic associations were assessed using Cox models, and survival distributions were compared with Kaplan–Meier analysis.</span></span></p> <p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Calibri"><strong>Results:</strong> Mean age at diagnosis was 52.3 ± 17.2 years, and 69.2% were female (n=54). WHO functional class III–IV was present in 79.5% of pts. Fourteen pts (18%) reached the composite endpoint.<br /> In univariate analysis, REVEAL Lite (HR 1.56, p=0.004) and COMPERA (HR 4.97, p=0.003) were significantly associated with adverse outcomes. Among hemodynamic variables, right-atrial pressure (RAP; p=0.010) and SvO2 (p=0.003) were significant predictors, and pulmonary arterial compliance (PAC) showed a borderline association (p=0.066).</span></span></p> <p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Calibri">In multivariable models including REVEAL, Cox regression identified three independent predictors: higher RAP (HR 1.17; 95% CI 1.05–1.29; p=0.003), lower PAC (HR 19.43; 95% CI 1.86–202.63; p=0.013), and higher REVEAL score (HR 1.54; 95% CI 1.12–2.12; p=0.003).<br /> In the model including COMPERA, independent predictors were RAP (HR 1.19; 95% CI 1.07–1.33; p=0.002), PAC (HR 15.79; 95% CI 1.44–172.64; p=0.024), and COMPERA score (HR 3.86; 95% CI 1.16–12.84; p=0.027). Clinically meaningful increments showed that each 1-mmHg increase in RAP conferred a 17–19% increase in hazard, and that PAC remained a very strong predictor in both models.</span></span></p> <p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Calibri">In the REVEAL intermediate-risk subgroup, SvO2 and RAP provided significant prognostic discrimination (Log-Rank p=0.005 and p=0.027, respectively) (Figure 1).</span></span></p> <p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Calibri"><strong>Conclusions:</strong> RAP, SvO2, and PAC significantly enhance risk discrimination beyond REVEAL and COMPERA, supporting the integration of invasive hemodynamics into routine multiparametric risk assessment.</span></span></p>
Slides
Our mission: To reduce the burden of cardiovascular disease
Visit our site